Swiss National Bank Acquires New Position in Bioventus Inc. (NYSE:BVS)

Swiss National Bank bought a new position in shares of Bioventus Inc. (NYSE:BVS) during the fourth quarter, HoldingsChannel reports. The firm bought 70,500 shares of the company’s stock, valued at approximately $740,000.

Several other hedge funds also recently made changes to their positions in the company. Quest Partners LLC acquired a new stake in shares of Bioventus during the 3rd quarter valued at approximately $51,000. Intech Investment Management LLC bought a new stake in Bioventus during the third quarter valued at $167,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Bioventus by 38.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after purchasing an additional 109,359 shares during the period. FMR LLC lifted its position in shares of Bioventus by 21,256.6% in the 3rd quarter. FMR LLC now owns 166,795 shares of the company’s stock worth $1,993,000 after buying an additional 166,014 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in shares of Bioventus by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 22,981 shares of the company’s stock valued at $275,000 after buying an additional 12,949 shares during the period. Institutional investors and hedge funds own 62.94% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Robert E. Claypoole sold 28,786 shares of Bioventus stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $261,952.60. Following the sale, the chief executive officer now directly owns 64,964 shares in the company, valued at $591,172.40. The trade was a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Leonard Singleton sold 6,498 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the sale, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at $1,210,745.23. The trade was a 5.19 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,161 shares of company stock worth $436,364. Insiders own 32.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on BVS shares. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and raised their target price for the stock from $12.00 to $13.00 in a report on Tuesday, December 17th. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Bioventus Stock Down 0.7 %

BVS stock opened at $9.03 on Friday. The stock has a market cap of $739.95 million, a PE ratio of -14.80 and a beta of 0.86. The firm’s 50-day simple moving average is $10.07 and its 200 day simple moving average is $10.98. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.